Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin versus placebo for systemic inflammation and neutrophil dysfunction in cirrhosis with chronic hepatic encephalopathy
2013-004708-20Phase 4Completed
- Sponsor
- King's College London
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in hepatic encephalopathy (HE) and Cirrhosis comparing Targaxan with Placebo (2 arms). Primary endpoint: Reduction in spontaneous neutrophil oxidative burst. Started Mar 2014; status: completed.
02
Drugs
rifaximin alpha
03
Conditions
hepatic encephalopathy (HE)Cirrhosis
Beyond the preview
Go deeper on 2013-004708-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004708-20.